Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior day. This move outpaced the S&P 500’s daily gain of 0.11%. Elsewhere, the Dow saw a downswing of 0.13%, while the tech-heavy Nasdaq appreciated by 0.18%.<\/p>\n
Shares of the drugmaker witnessed a loss of 5.25% over the previous month, beating the performance of the Medical sector with its loss of 6.43%, and underperforming the S&P 500’s loss of 4.28%.<\/p>\n
The upcoming earnings release of Novo Nordisk will be of great interest to investors. In that report, analysts expect Novo Nordisk to post earnings of $0.87 per share. This would mark a year-over-year decline of 5.43%. Simultaneously, our latest consensus estimate expects the revenue to be $11.06 billion, showing a 0.48% escalation compared to the year-ago quarter.<\/p>\n
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $45.1 billion, signifying shifts of -15.15% and -3.59%, respectively, from the last year.<\/p>\n
Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.<\/p>\n
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.<\/p>\n
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.04% lower. Currently, Novo Nordisk is carrying a Zacks Rank of #3 (Hold).<\/p>\n
Valuation is also important, so investors should note that Novo Nordisk has a Forward P\/E ratio of 10.87 right now. This signifies a discount in comparison to the average Forward P\/E of 14.79 for its industry.<\/p>\n
We can additionally observe that NVO currently boasts a PEG ratio of 8.63. The PEG ratio is similar to the widely-used P\/E ratio, but this metric also takes the company’s expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.36 as trading concluded yesterday.<\/p>\n
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 158, positioning it in the bottom 36% of all 250+ industries.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior…\n","protected":false},"author":2,"featured_media":51887,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,13101,1278],"class_list":["post-54407","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-pharmaceuticals-industry","tag-zacks-rank"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116337704063517154","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=54407"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54407\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/51887"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=54407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=54407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=54407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}